ABSTRACT Guanfacine, a noradrenergic alpha2a agonist, reduced tobacco smoking in a 4-week trial and in animal models has been shown to reduce cortical dopamine release, which is critically

involved in the reinforcing effect of tobacco smoking. We measured amphetamine-induced extrastriatal dopamine release before and after treatment with guanfacine with [11C]FLB457, a dopamine

D2/D3 receptor radiotracer, and positron emission tomography (PET). Sixteen tobacco smokers had one set of [11C]FLB457 PET scans on the same day, one before and one at 2.5–3 h after

amphetamine (0.4–0.5 mg/kg, PO). A subset (_n_=12) then underwent guanfacine treatment (3 mg/day for 3 weeks) and the set of scans were repeated. [11C]FLB457-binding potential (_BP_ND) was

baseline _BP_ND from the untreated to the guanfacine-treated condition. Chronic guanfacine treatment reduced [11C]FLB457 _BP_ND in tobacco smokers, suggesting an increase in dopaminergic

tone. Guanfacine-induced normalization of dopamine signaling may be an important mesocortical mechanism contributing to its ability to aid in tobacco smoking cessation. SIMILAR CONTENT BEING

VIEWED BY OTHERS THE INFLUENCE OF CONDITIONED STIMULI ON [11C]-(+)-PHNO PET BINDING IN TOBACCO SMOKERS AFTER A ONE WEEK ABSTINENCE Article Open access 03 June 2021 CHOLINERGIC TONE

ABNORMALITIES AND RELATIONSHIPS WITH SMOKING SEVERITY IN HUMAN CIGARETTE SMOKERS: EXPLORATORY POSITRON EMISSION TOMOGRAPHY STUDY USING [18F]VAT Article 31 March 2025 EXPLORING REGULATION AND

FUNCTION OF DOPAMINE D3 RECEPTORS IN ALCOHOL USE DISORDER. A PET [11C]-(+)-PHNO STUDY Article 04 August 2021 INTRODUCTION Tobacco smoking continues to be the leading cause of preventable

premature disease and death in the United States, with smoking-related illnesses claiming the lives of more than 556 000 people annually and contributing to 20 million deaths since the first

Surgeon General’s report 50 years ago (US Department of Health and Human Services, 2014). Despite overwhelming evidence of the adverse health consequences associated with tobacco smoking,

~18% of adults in the United States continue to smoke, and the vast majority of those who attempt to quit relapse within the first month (Benowitz, 2009). The main addictive chemical in

tobacco smoke is nicotine, which acts at _β_2-nicotinic acetylcholine receptors (_β_2-nAChRs) and facilitates the release of dopamine (Cosgrove et al, 2015) in limbic and cortical brain

regions. Nicotine replacement therapies (NRTs), eg, the nicotine patch, which mimic the effects of nicotine, have been only moderately effective in helping smokers quit. This suggests that

additional neuronal mechanisms that underlie aspects of relapse (eg, stress or cognitive dysfunction) should be targeted for more effective smoking cessation treatments. Alpha2 adrenergic

agonists, including guanfacine, have the potential to treat tobacco dependence, as indicated by their ability to attenuate nicotine-related reinforcement, cue-induced craving, and

stress-related effects, as well as to improve cognitive function (Bruijnzeel et al, 2010; Fox et al, 2012; Hains et al, 2015; McKee et al, 2015; Yamada and Bruijnzeel, 2011). Currently,

guanfacine is used to treat cognitive disorders with a prefrontal cortical (PFC) dysfunction, and it is approved for the treatment of attention-deficit/hyperactivity disorder (Arnsten and

Jin, 2012) and hypertension. Guanfacine improves cognition (ie, working memory) and reduces stress reactivity through the inhibition of norepinephrine and the modulation of dopamine

neurotransmission (Arnsten and Pliszka, 2011) particularly along the PFC–amygdala axis. Preclinical studies have demonstrated that guanfacine and clonidine, both alpha2 adrenergic agonists,

reduced drug-induced dopamine release in the PFC (Jentsch et al, 2008; Jentsch et al, 1998). A recent study in tobacco smokers demonstrated that treatment with guanfacine _vs_ placebo

decreased stress-induced smoking in the laboratory, altered PFC neural activation in areas associated with attention and inhibitory control, and reduced cigarette use (McKee et al, 2015).

Thus, guanfacine may be a potential treatment to prevent relapse during smoking cessation, however, the effect of guanfacine on dopamine neurotransmission in humans has not yet been studied.

Positron emission tomography (PET) brain imaging with the radiotracer [11C]FLB457, a high-affinity dopamine D2/D3 receptor antagonist, can be used to quantify availability of dopamine D2/D3

receptors and changes in synaptic dopamine levels in extra-striatal regions of the brain (Sandiego et al, 2015). The objective of this study was to examine the effects of guanfacine

treatment on dopamine neurotransmission in healthy tobacco smokers with [11C]FLB457 and PET. We used amphetamine as a pharmacological probe to elicit dopamine release in the brain and we

measured amphetamine-induced changes in [11C]FLB457 binding before and at the end of 3 weeks of daily guanfacine administration. We hypothesized that guanfacine treatment would reduce

amphetamine-induced dopamine release in the dorsolateral prefrontal cortex (dlPFC) and the amygdala. We chose dlPFC and amygdala as primary regions of interest based on studies indicating a

role for guanfacine in modulating dopamine neurotransmission in the PFC and the PFC–amygdala axis (Arnsten and Pliszka, 2011; Jentsch et al, 2008). We tailored our choice of PET radiotracer

accordingly, as [11C]FLB457 is used to measure extra-striatal dopamine D2/D3 receptor availability. MATERIALS AND METHODS PARTICIPANTS Sixteen tobacco smokers (6 female and 10 male, 37±9

years old) participated in a set of [11C]FLB457 PET scans, one scan before, and a second scan 3 h after, amphetamine administration. Fifteen of these subjects had their baseline and

post-amphetamine scans on the same day. Due to radiochemistry issues, one subject had the amphetamine administration and post-amphetamine scan 5 days after the baseline scan. Twelve (4

female, 8 male) of the sixteen subjects came back for a second set of pre- and post-amphetamine scans, performed on the same day, at the end of 3 weeks of guanfacine treatment. On both study

days all subjects were required to abstain from smoking overnight, which was verified by carbon monoxide levels <11 ppm or a carbon monoxide level that was ⩽50% of their intake level.

All subjects had one magnetic resonance scan as previously described (Sandiego et al, 2015), required to delineate anatomical information from the PET data for brain region-of-interest

analysis. Subjects for this imaging study were recruited from an ongoing human laboratory study in tobacco smokers investigating the effects of treatment with guanfacine on

stress-precipitated smoking behavior. All subjects provided written informed consent for participation in the study. The study adhered to the Protection of Human Subjects of Research and

Ethical Principles and Guidelines. The Human Investigation Committee, Yale University School of Medicine, and Yale-New Haven Hospital Radiation Safety granted approval for the study

protocol. CLINICAL ASSESSMENT Subjects were medically and psychiatrically healthy. Eligibility was determined by the study PI and the study physician and included the following: a medical

examination including a physical examination, electrocardiogram, serum chemistries, thyroid function studies, complete blood count, urinalysis, and urine toxicology screening. Participants

had no history of significant medical illness or major head trauma. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-IV) was administered to

rule out Axis I Disorders including Substance and Alcohol Dependence but not Nicotine Dependence. Tobacco smokers were required to have been smoking at least 10 cigarettes daily for at least

1 year, and during screening to have carbon monoxide levels greater than 10 ppm and urine cotinine levels >150 ng/ml. Women had negative pregnancy tests during screening and prior to

each radiotracer injection. Menstrual cycle phase was not controlled and hormonal contraception was not exclusionary. [11C]FLB457 PET IMAGING [11C]FLB457 was synthesized as previously

described (Sandiego et al, 2015). The specific activity (mean±SD) was 32.4±27.2 mCi/nmol at end of synthesis and 17.6±15.4 mCi/nmol at time of injection (_n_=56). Injected dose of

[11C]FLB457 across scans was 9.1±1.8 mCi (_n_=56). PET scans were performed on the ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN, USA). A 6-min transmission scan was acquired prior to the start

of each PET acquisition for attenuation correction. [11C]FLB457 was injected intravenously as a bolus over 1-min by a computer-controlled pump (Harvard Apparatus, Holliston, MA, USA), and

emission data were collected for 90 min. Sinograms were reconstructed with all corrections (attenuation, normalization, scatter, randoms, and deadtime) into a sequence of 27 frames: 6 × 30 

s; 3 × 1 min; 2 × 2 min; 16 × 5 min. Final image dimension and voxel size were 128 × 128 × 63 and 2.06 × 2.06 × 2.43 mm3, respectively. Motion-correction on the dynamic data was performed by

registering each frame to an early frame (ie, the first 10 min of data post injection) using a six-parameter mutual information algorithm (Viola and Wells, 1997) (FMRIB’s Linear Image

Registration Tool, FMRIB Software library, version 3.2). The final reconstructed image resolution was ~6 mm full-width at half maximum. AMPHETAMINE ADMINISTRATION AND PLASMA LEVELS

Amphetamine (0.4–0.5 mg/kg, PO) was administered 150–180 min prior to the second [11C]FLB457 injection, in order that the peak of amphetamine levels in the plasma lined up in time with the

second PET scan, based on the previous work (Narendran et al, 2013). Relative to amphetamine administration (_t_=0 min), blood samples were collected at _t_=60, 120, 180, 240, and 270 min.

Of the 16 total subjects, 2 received 0.5 mg/kg and participated in both scanning sessions, ie, before and after guanfacine treatment. Because there was evidence for an interaction between

chronic guanfacine treatment and amphetamine, the dose of amphetamine was lowered to 0.4 mg/kg after the first two subjects. The details of the interaction have been previously published

(Gaiser et al, 2015). The study was stopped after 12 subjects completed the post-guanfacine scan set because there was evidence for an interaction between guanfacine and amphetamine, even at

the reduced amphetamine dose. GUANFACINE TREATMENT After the first set of PET scans (untreated condition), subjects underwent treatment with guanfacine as previously described (McKee et al,

2015). Guanfacine was administered PO twice daily for 21 days and was titrated to steady-state levels of 3 mg/day. Subsequently, the second set of PET scans (guanfacine-treated condition)

was performed to assess the effect of chronic guanfacine on amphetamine-induced dopamine release. Subjects were not asked to modify their cigarette intake during the 3-week trial. Medication

compliance was assessed with a riboflavin marker, and urine florescence was assessed every 2–3 days during the 3-week period. PET IMAGE PROCESSING AND ANALYSIS Regions of interest (ROIs)

were mapped from Montreal Neurological Institute (MNI) template space to PET space to compute tissue time-activity curves, as described previously (Sandiego et al, 2015). Our primary ROIs of

dlPFC and amygdala were chosen _a priori_. We included as secondary analysis the following extrastriatal ROIs, which have measureable specific signal (ie, _BP_ND>0.5) (Narendran et al,

2009), for comparison to other current (Narendran et al, 2009) and future studies in the literature: cingulum, hippocampus, occipital cortex, parietal cortex, temporal cortex, and thalamus.

The simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) was used for the kinetic analysis of non-displaceable binding potential (_BP_ND) as previously described (Sandiego et

al, 2015), using the cerebellum as the reference region. Percent change in _BP_ND (%Δ_BP_ND) from baseline to amphetamine challenge, an indirect measure of dopamine release, was computed

as: %Δ_BP_ND=[1−_BP_ND(challenge)/_BP_ND(baseline)] × 100 for both untreated and guanfacine-treated conditions in the ROIs examined. CLINICAL LABORATORY MEASUREMENT There were 11 subjects

who completed both imaging and laboratory sessions. Subjects completed a laboratory session examining withdrawal-precipitated smoking behavior on ability to resist smoking and ad-lib

self-administration, as previously described (neutral session (McKee et al, 2015)). See Supplementary Figure 1 for a timeline of procedures. Subjects abstained from smoking overnight before

the laboratory session, 15 h from their last cigarette. To assess smoking lapse, subjects were presented with eight cigarettes of their preferred brand and could choose to smoke at any point

within 50 min (delay period). Subjects were rewarded $1 for every 5 min they resisted smoking during the 50 min delay period. Once subjects decided to start smoking, or resisted smoking for

the full 50 min, a 60 min ad-libitum session commenced. Primary outcomes examined included latency to start smoking (ie, ability to resist smoking) and number of cigarettes smoked during

the 60-min self-administration session. STATISTICAL ANALYSIS _T_-tests were used to evaluate potential differences in injected dose and injected mass between scans. Using a multiple

dependent general linear model across all brain regions, we examined whether there was a significant difference between the change in _BP_ND from the untreated to the guanfacine-treated

condition. This omnibus test capped the type 1 error rate at alpha<0.05 (one-tailed). Based on our _a priori_ hypothesis that guanfacine improves cognition and reduces stress reactivity

via the PFC–amygdala axis, we examined differences in the amygdala and dlPFC with _a priori_ contrasts. All other brain regions were examined with _post hoc_ testing correcting for multiple

comparisons. Basic demographic (sex, age) and smoking variables (cigarettes per day, Fagerström Test for Nicotine Dependence (FTND) scores) were evaluated as potential covariates, and were

only retained if they reduced residual variance. Sex was the only variable retained as a covariate. Using a general linear model across all brain regions, we also evaluated whether there was

a significant baseline (pre-amphetamine) difference between the untreated to the guanfacine-treated conditions. Given our _a priori_ hypothesis concerning the amygdala and dlPFC, Pearsons

correlation coefficients were used to examine relationships between _BP_ND values and clinical correlates of tobacco smoking and treatment outcomes. RESULTS Across all subjects (_n_=16),

cigarettes smoked per day and number of years smoked were 13.0±5.4 no./day and 17.0±6.6 years, respectively, with a mean FTND score of 5.4±3.0. On the day of the scan, carbon monoxide and

urine cotinine levels were 8.4±3.9 ppm and 967±129 ng/ml (_n_=16) in the untreated condition and 9.1±6.0 ppm and 812±252 ng/ml (_n_=12) in the guanfacine-treated condition. There were no

significant carbon monoxide or cotinine level differences between pre- and post-guanfacine conditions. PET SCAN PARAMETERS There were no significant differences in injected dose between pre-

and post-amphetamine [11C]FLB457 scans, respectively, under untreated (9.2±1.4 and 9.0±2.0 mCi) and guanfacine-treated (9.9±0.4 and 9.1±1.8 mCi) conditions. No significant differences were

found in injected mass between pre- and post-amphetamine [11C]FLB457 scans, respectively, in the untreated (0.39±0.16 and 0.44±0.14 μg) and guanfacine-treated (0.31±0.13 and 0.34±0.20 μg)

groups. PLASMA AMPHETAMINE LEVELS Amphetamine levels were measured in the plasma after amphetamine administration on both scan days, and there were no differences between the group of

subjects scanned in the untreated (_n_=16) and guanfacine-treated (_n_=12) conditions (ie, 52.3±2.3 and 51.3±4.3 ng/ml at 180 min). The post-amphetamine [11C]FLB457 PET scans started at

150–180 min after amphetamine administration, which coincided with the peak amphetamine levels which then remained elevated through the duration of the scan at 240–270 min (Figure 1). EFFECT

OF GUANFACINE ON EXTRASTRIATAL AMPHETAMINE-INDUCED DOPAMINE RELEASE For both sets of scans, amphetamine reduced [11C]FLB457 _BP_ND relative to baseline in all ROIs examined, indicative of

an increase in dopamine levels (Table 1). We examined whether the Δ_BP_ND was lower in the guanfacine-treated condition _vs_ the untreated condition, ie did guanfacine treatment attenuate

the amphetamine-induced dopamine release? We found that the Δ_BP_ND was significantly reduced in the amygdala after guanfacine treatment (from 8 to 2%) [F(1,10)=3.92, _p_=0.038; see Table 1,

Figure 2], but not in the dlPFC or other brain regions. EFFECT OF GUANFACINE ON BASELINE DOPAMINE D2/D3 RECEPTOR AVAILABILITY We examined whether the reduction in amphetamine-induced

dopamine release from the untreated to the guanfacine-treated condition was due to a change in baseline _BP_ND. We found that guanfacine treatment significantly decreased baseline _BP_ND

across the ROIs examined [F(3,8)=6.58, _p_=0.038], however, the _BP_ND differences within specific regions did not reach significance (Figure 2). After treatment with guanfacine, there was a

9% reduction in baseline _BP_ND (eg, 4% in thalamus, 8% in the amygdala, and 12% in dlPFC), averaged across all ROIs and all subjects (_n_=16 pre-treatment and _n_=12 post treatment). We

had the same finding when comparing the baseline _BP_ND in the same 12 subjects before and after treatment with guanfacine (Supplementary Figure 2). CLINICAL MEASURES Difference scores in

baseline _BP_ND during the untreated to the guanfacine-treated condition were calculated for all regions to explore relationships between the change in _BP_ND with treatment outcomes. There

was a significant correlation between the difference in baseline amygdala values from the untreated to treated condition with the latency to start smoking (_r_=0.73, _p_=0.01) and with

number of cigarettes smoked in the self-administration phase (_r_=−0.62, _p_=0.04). A bigger change in _BP_ND was associated with a longer latency to smoke and fewer cigarettes smoked during

self-administration. There were no other relationships between _BP_ND or Δ_BP_ND in the regions of interest with clinical characteristics of tobacco smoking. DISCUSSION In the current study

we found that, in tobacco smokers, treatment with guanfacine significantly reduced amphetamine-induced dopamine release in the amygdala, as measured with PET brain imaging and the

radiotracer [11C]FLB457. However, this reduction in the amygdala, dlPFC, and other regions examined was primarily due to a reduction in baseline _BP_ND after chronic guanfacine treatment,

which is indicative of an increase in dopaminergic tone as a result of treatment. Specifically, the reduction in _BP_ND from pre-to post-guanfacine treatment suggests that dopamine levels

have increased (Morris et al, 2014; Volkow et al, 2009). Furthermore, the increase in dopaminergic tone in the amygdala following treatment correlated with clinical outcomes, specifically

longer latency to smoke and fewer cigarettes smoked during a self-administration period. This suggests that one mechanism by which guanfacine may help smokers quit smoking is by modulating

dopaminergic neurotransmission. Guanfacine is an approved medication for ADHD and has been investigated as a means to treat other cognitive and stress-related disorders such as PTSD and

substance abuse (Arnsten and Pliszka, 2011; Arnsten et al, 2015; Fox et al, 2014). The dlPFC is particularly sensitive to catecholamine levels (Arnsten, 2011), and aberrant norepinephrine

and dopamine levels, such as are found in cognitive and stress-related disorders, can compromise the ability to manage arousal and executive function. Arnsten _et al_ (2015) have studied the

neurobiology of stress extensively as it relates to cognition. In general, acute stress increases norepinephrine and dopamine release, which weakens performance of the dlPFC and impairs

executive function and at the same time strengthens the amygdala so that more primitive emotional and habitual responding can take over. Guanfacine, an alpha2a adrenergic agonist, inhibits

norepinephrine release, cAMP-signaling and HCN potassium channel function, which in turn is thought to normalize the balance of norepinephrine and dopamine between the amygdala and PFC (ie,

the PFC–amygdala axis), thus reducing stress reactivity and improving cognitive function. Indeed, a previous study in smokers found that guanfacine treatment altered PFC activity, measured

with fMRI, during a cognitive control task and reduced cigarette consumption and craving in the laboratory, compared with placebo (McKee et al, 2015). In line with this finding, in the

current study, guanfacine treatment appears to have increased, and possibly normalized, baseline dopaminergic tone. Therefore, modulating neurochemistry in the PFC–amygdala axis, with

guanfacine or a similar medication, may be an important mechanism to manage some of the adverse consequences of tobacco smoking cessation, such as the inability to manage stress and

behavioral disinhibition. In the context of tobacco smoking, nicotine is the primary addictive component and exerts its primary reinforcing effects by activating _β_2-nAChRs in the

mesolimbic dopamine pathway (Picciotto et al, 1998), but nicotine also modifies cognitive function and stress responses, through activation of nAChRs in the cortico-limbic pathway

(Mansvelder et al, 2009). Tobacco smokers (Fehr et al, 2008) along with individuals dependent on other drugs of abuse (Martinez et al, 2004, 2005; Zijlstra et al, 2008), tend to have lower

striatal dopamine D2/D3 receptor availability and, in some cases a ‘blunted’ striatal dopamine response (Martinez et al, 2005). This is thought to indicate a general reward circuit deficit,

which may make it difficult for recovering substance abusers to effectively transition from drug rewards to natural reward. Dopaminergic function in extrastriatal brain regions of tobacco

smokers and drug abusers has not been well characterized. This study is limited by the lack of a nonsmoker control comparison group. While we cannot determine whether tobacco smokers have a

‘blunted’ dopamine response compared to nonsmokers, our study does indicate that guanfacine treatment appears to increase extrastriatal dopamine tone. While we interpret our finding of a

decrease in _BP_ND as an increase or ‘normalization’ of dopaminergic tone by chronic guanfacine treatment, there is a caveat. Specifically, a decrease in _BP_ND could also be interpreted as

a downregulation of dopamine D2/D3 receptors. Interestingly, in nonhuman primates, there was a positive correlation between [11C]raclopride binding (a radioligand to measure dopamine D2/D3

receptors in the striatum) and severity of self-injurious behavior (Freeman et al, 2015). Guanfacine treatment reduced self-injurious behaviors and improved cognition suggesting a

restoration of dopamine levels. In addition, data exist to indicate that guanfacine treatment increases dopamine levels in the PFC (Arnsten, 2011). Thus, we presume that activation of

noradrenergic alpha-2a receptors with guanfacine reduces dopamine D2/D3 receptor availability by increasing basal dopamine levels. Additionally, with this imaging paradigm, we initially

hypothesized that treatment with guanfacine would blunt amphetamine-induced dopamine release in the amygdala and dlPFC. Indeed, the amphetamine-induced reduction in [11C]FLB457 _BP_ND was

less after treatment with guanfacine across all regions and the difference reached significance in the amygdala, but overall this appears to be due to a significant reduction in

post-treatment baseline levels of [11C]FLB457 _BP_ND. The reduction in amphetamine-induced dopamine release in the amygdala is important because this is a region known to play a key role in

regulating stress, thus chosen for investigation _a priori_. However, all other regions examined followed the same trend, but did not reach significance after correcting for multiple

comparisons. Thus, it is not completely clear whether the reduction in amphetamine-induced dopamine release by guanfacine is restricted to the amygdala. This study was discontinued due to

the interaction between amphetamine and guanfacine that increased sympathetic tone in some subjects resulting in hypertension, even when the amphetamine dose was 0.4 mg/kg (Gaiser et al,

2015). Thus, due to the limited number of subjects in this study, we were not able to examine sex differences. Another limitation is that the relatively high affinity of [11C]FLB457 for

dopamine D2/D3 receptors does not permit reliable measurements of binding (ie, does not achieve equilibrium during the scan duration) in the striatum, a region that is commonly studied in

addiction research as part of the mesolimbic dopamine system. A recently published study found that healthy nonsmokers who underwent treatment with prazosin, an alpha 1 adrenergic

antagonist, had increased [11C]PHNO (D3 receptor agonist) binding in the dorsal caudate from baseline, indicative of a decrease in dopamine levels (Le Foll et al, 2017). Guanfacine and

prazosin act through different mechanisms (ie, alpha 2a agonist and alpha 1 antagonist, respectively) to restore the balance of norepinephrine and dopamine levels, and both have been studied

for the treatment of stress related disorders (Arnsten et al, 2015). The effect of guanfacine treatment on striatal binding and dopamine could be examined in a future study with a

radiotracer that allows stable _BP_ND measurements in striatum, eg, [11C]raclopide, [11C]PHNO, or [18F]fallypride. In conclusion, guanfacine-induced normalization of dopaminergic tone may be

an important treatment mechanism for smoking cessation. We have demonstrated in tobacco smokers that chronic guanfacine treatment reduces dopamine D2/D3 receptor availability in

extrastriatal brain regions, measured _in vivo_ with [11C]FLB457 PET imaging. This finding is indicative of an overall increase in dopamine levels after 3 weeks of guanfacine treatment. Our

study further supports targeting the noradrenergic system with guanfacine as a mechanism to regulate mesocortical activity for the treatment of tobacco smoking. FUNDING AND DISCLOSURE

Research Support: NIDA grant K02DA031750 and the ORWH/NIDA grant P50DA033945. The authors declare no conflict of interest. REFERENCES * US Department of Health and Human Services (2014).

_The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General_. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and

Health: Atlanta, GA. * Arnsten AF (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. _Biological Psychiatry_ 69: e89–e99. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Arnsten AF, Jin LE (2012). Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. _The Yale Journal Of Biology And Medicine_ 85: 45–58. CAS

  PubMed  PubMed Central  Google Scholar  * Arnsten AF, Pliszka SR (2011). Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity

disorder and related disorders. _Pharmacol Biochem Behav_ 99: 211–216. Article  CAS  PubMed  PubMed Central  Google Scholar  * Arnsten AF, Raskind MA, Taylor FB, Connor DF (2015). The

effects of stress exposure on prefrontal cortex: translating basic research into successful treatments for post-traumatic stress disorder. _Neurobiol Stress_ 1: 89–99. Article  PubMed 

Google Scholar  * Benowitz NL (2009). Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. _Annu Rev Pharmacol Toxicol_ 49: 57–71. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Bruijnzeel AW, Bishnoi M, van Tuijl IA, Keijzers KF, Yavarovich KR, Pasek TM _et al_ (2010). Effects of prazosin, clonidine, and propranolol on the elevations in

brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. _Psychopharmacology_ 212: 485–499. Article  CAS  PubMed  PubMed Central  Google Scholar  * Cosgrove KP,

Esterlis I, Sandiego C, Petrulli R, Morris ED (2015). Imaging tobacco smoking with PET and SPECT. _Curr Topics Behav Neurosci_ 24: 1–17. Article  CAS  Google Scholar  * Fehr C, Yakushev I,

Hohmann N, Buchholz HG, Landvogt C, Deckers H _et al_ (2008). Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of

abuse. _Am J Psychiatry_ 165: 507–514. Article  PubMed  Google Scholar  * Fox HC, Morgan PT, Sinha R (2014). Sex differences in guanfacine effects on drug craving and stress arousal in

cocaine-dependent individuals. _Neuropsychopharmacology_ 39: 1527–1537. Article  CAS  PubMed  PubMed Central  Google Scholar  * Fox HC, Seo D, Tuit K, Hansen J, Kimmerling A, Morgan PT _et

al_ (2012). Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. _J Psychopharmacol_ 26: 958–972. Article  PubMed 

PubMed Central  Google Scholar  * Freeman ZT, Rice KA, Soto PL, Pate KA, Weed MR, Ator NA _et al_ (2015). Neurocognitive dysfunction and pharmacological intervention using guanfacine in a

rhesus macaque model of self-injurious behavior. _Transl Psychiatry_ 5: e567. Article  CAS  PubMed  PubMed Central  Google Scholar  * Gaiser EC, Matuskey D, Perkins E, D'Amico C,

Abdelghany O, McKee SA _et al_ (2015). A case series on the heightened autonomic response due to guanfacine and amphetamine interaction. _J Clin Psychopharmacol_ 35: 197–199. Article  PubMed

  PubMed Central  Google Scholar  * Hains AB, Yabe Y, Arnsten AF (2015). Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and

cognition from the effects of chronic stress. _Neurobiol Stress_ 2: 1–9. Article  PubMed  PubMed Central  Google Scholar  * Jentsch JD, Sanchez D, Elsworth JD, Roth RH (2008). Clonidine and

guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype. _Brain Res_ 1246: 41–46. Article  CAS  PubMed

  PubMed Central  Google Scholar  * Jentsch JD, Wise A, Katz Z, Roth RH (1998). Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol-induced

increases in dopamine utilization in rat prefrontal cortex. _Synapse_ 28: 21–26. Article  CAS  PubMed  Google Scholar  * Lammertsma AA, Hume SP (1996). Simplified reference tissue model for

PET receptor studies. _NeuroImage_ 4 (3 Pt 1): 153–158. Article  CAS  PubMed  Google Scholar  * Le Foll B, Thiruchselvam T, Lu SX, Mohammed S, Mansouri E, Lagzdins D _et al_ (2017).

Investigating the effects of norepinephrine alpha1 receptor blockade on dopamine levels: a pilot PET study with [11 C]-(+)-PHNO in controls. _Synapse_ 71. * Mansvelder HD, Mertz M, Role LW

(2009). Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. _Semin Cell Dev Biol_ 20: 432–440. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y _et al_ (2004). Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship

with cocaine-seeking behavior. _Neuropsychopharmacology_ 29: 1190–1202. Article  CAS  PubMed  Google Scholar  * Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A _et al_ (2005).

Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. _Biol Psychiatry_ 58: 779–786. Article  CAS  PubMed  Google Scholar  * McKee SA, Potenza MN,

Kober H, Sofuoglu M, Arnsten AF, Picciotto MR _et al_ (2015). A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking

cessation. _J Psychopharmacol_ 29: 300–311. Article  CAS  PubMed  Google Scholar  * Morris ED, Lucas MV, Petrulli JR, Cosgrove KP (2014). How to design PET experiments to study

neurochemistry: application to alcoholism. _Yale J Biol Med_ 87: 33–54. PubMed  PubMed Central  Google Scholar  * Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE _et al_

(2009). Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB

457 and [11C]fallypride. _Synapse_ 63: 447–461. Article  CAS  PubMed  Google Scholar  * Narendran R, Himes M, Mason NS (2013). Reproducibility of post-amphetamine [11C]FLB 457 binding to

cortical D2/3 receptors. _PLoS ONE_ 8: e76905. Article  CAS  PubMed  PubMed Central  Google Scholar  * Picciotto M, Zoli M, Rimondin R, Lena C, Marubio L, Pich E _et al_ (1998). Acetycholine

receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. _Nature_ 391: 173–177. Article  CAS  PubMed  Google Scholar  * Sandiego CM, Gallezot JD, Lim

K, Ropchan J, Lin SF, Gao H _et al_ (2015). Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET. _J Cereb Blood Flow Metab_ 35: 623–629. Article

  CAS  PubMed  PubMed Central  Google Scholar  * Viola P, Wells WM (1997). Alignment by maximization of mutual information. _Int J Comput Vision_ 24: 137–154. Article  Google Scholar  *

Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009). Imaging dopamine’s role in drug abuse and addiction. _Neuropharmacology_ 56 (Suppl 1): 3–8. Article  CAS  PubMed  Google Scholar  *

Yamada H, Bruijnzeel AW (2011). Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats.

_Neuropharmacology_ 60: 303–311. Article  CAS  PubMed  Google Scholar  * Zijlstra F, Booij J, van den Brink W, Franken IH (2008). Striatal dopamine D2 receptor binding and dopamine release

during cue-elicited craving in recently abstinent opiate-dependent males. _Eur Neuropsychopharmacol_ 18: 262–270. Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS

The authors would like to thank Erin McGovern, Evgenia Perkins, Ansel Hillmer, and Yasmin Zakiniaeiz and the staff at the Yale PET Center. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Department of Psychiatry, Yale University, New Haven, CT, USA Christine M Sandiego, David Matuskey, Meaghan Lavery, Erin McGovern, Marina R Picciotto, Evan D Morris, Sherry A McKee & 

Kelly P Cosgrove * PET Center, Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA Christine M Sandiego, David Matuskey, Yiyun Huang, Nabeel Nabulsi, Jim Ropchan, Evan D

Morris & Kelly P Cosgrove * Department of Biomedical Engineering, Yale University, New Haven, CT, USA Evan D Morris Authors * Christine M Sandiego View author publications You can also

search for this author inPubMed Google Scholar * David Matuskey View author publications You can also search for this author inPubMed Google Scholar * Meaghan Lavery View author publications

You can also search for this author inPubMed Google Scholar * Erin McGovern View author publications You can also search for this author inPubMed Google Scholar * Yiyun Huang View author

publications You can also search for this author inPubMed Google Scholar * Nabeel Nabulsi View author publications You can also search for this author inPubMed Google Scholar * Jim Ropchan

View author publications You can also search for this author inPubMed Google Scholar * Marina R Picciotto View author publications You can also search for this author inPubMed Google Scholar

* Evan D Morris View author publications You can also search for this author inPubMed Google Scholar * Sherry A McKee View author publications You can also search for this author inPubMed 

Google Scholar * Kelly P Cosgrove View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Kelly P Cosgrove. ADDITIONAL

INFORMATION Supplementary Information accompanies the paper on the Neuropsychopharmacology website SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE 1 (DOCX 73 KB) SUPPLEMENTARY FIGURE 2 (DOCX

39 KB) POWERPOINT SLIDES POWERPOINT SLIDE FOR FIG. 1 POWERPOINT SLIDE FOR FIG. 2 RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sandiego, C., Matuskey,

D., Lavery, M. _et al._ The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study. _Neuropsychopharmacol._ 43,

1052–1058 (2018). https://doi.org/10.1038/npp.2017.223 Download citation * Received: 07 April 2017 * Revised: 11 September 2017 * Accepted: 14 September 2017 * Published: 25 September 2017 *

Issue Date: April 2018 * DOI: https://doi.org/10.1038/npp.2017.223 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative